Xenetic Biosciences, Inc. current report, 04 December 2019

Xenetic Biosciences, Inc. - 8-K Filing Summary

Business Context and Reporting Period

This Form 8-K reports on the results of the 2019 Annual Meeting of Stockholders held by Xenetic Biosciences, Inc. on December 4, 2019. The Company is incorporated in Nevada and its common stock (XBIO) and purchase warrants (XBIOW) are listed on The NASDAQ Stock Market LLC.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.

Material Changes and Voting Results

Stockholders approved four key proposals at the Annual Meeting:

  • Election of Directors: All eight nominees were elected. Votes ranged from approximately 1,337,250 to 1,344,260 "For" votes, with "Withheld" votes ranging from 77,045 to 84,055.
  • Ratification of Auditors: Stockholders approved the selection of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019. The vote was 3,570,396 "For" versus 331,153 "Against".
  • Executive Compensation (Say-on-Pay): Stockholders approved the named executive officer compensation on a non-binding advisory basis. The vote was 752,022 "For" versus 656,734 "Against".
  • Equity Incentive Plan Amendment: Stockholders approved the Amended and Restated Equity Incentive Plan, increasing the authorized shares by 750,000. The vote was 832,623 "For" versus 132,926 "Against".

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies beyond the standard disclosure of the voting outcomes.

Investor Verification Checklist

  • Verify the final share count and ownership structure following the approval of the 750,000 share increase in the Equity Incentive Plan.
  • Review the full proxy statement for details on the specific compensation packages approved in the "Say-on-Pay" vote, which received a lower margin of approval compared to other proposals.
  • Confirm the commencement date of Marcum LLP's audit for the fiscal year ending December 31, 2019.
  • Check subsequent filings for any changes to the board composition or executive team following the annual meeting.